Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1

Journal of Infectious Diseases

Volumn 173, Issue 1, 1996, Pages 52-59

  Berman, Phillip W ^a   Murthy, Krishna K ^b   Wrin, Terri ^b   Vennari, Joann C ^b   Kathy Cobb, E ^b   Eastman, Donna J ^b   Champe, Mark ^b   Nakamura, Gerald R ^b   Davison, Donna ^b   Powell, Michael F ^b   Bussiere, Jeanine ^b   Francis, Donald P ^b   Matthews, Tom ^b   Gregory, Timothy J ^b   Obijeski, John F ^b  

^a GENENTECH INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

EID: 19144370387     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.1.52     Document Type: Article

References (17)

1. Schultz AM. HIV vaccine studies in the chimpanzee. AIDS Res Rev 1992;2:361-77.
2. Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990;345:622-5.
3. Girard M, Kieny MP, Pinter A, et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-6.
4. Fultz PN, Nara P, Barre-Sinoussi F, et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992;256:1687-90.
5. Bruck C, Thiriart C, Fabry L, et al. HIV-I envelope-elicited neutralizing antibody titers correlate with protection and virus in chimpanzees. Vaccine 1994;12:1141-8.
6. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW. Variable and conserved neutralizing antigen of human immunodeficiency virus. Nature 1986;324:572-5.
7. Berman PW, Groopman JE, Gregory T, et al. HIV-1 challenge of chimpanzees immunized with recombinant gp120. Proc Natl Acad Sci USA 1988;85:5200-4.
8. La Rosa GJ, Davide JP, Weinhold K, et al. Conserved sequences and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-5.
9. Berman PW, Matthews TJ, Riddle L, et al. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate. J Virol 1992;7:4464-9.
10. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-80.
11. Cohen J. Is NIH failing an AIDS "challenge"? [news] Science 1991;251:518-20.
12. Murthy KK, Cobb KE, El-Amad Z, et al. Titration of an HIV-1 SF2 virus stock in chimpanzees. In: Program and abstracts: Sixth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS: Conference on Advances in AIDS Vaccine Development (Alexandria, VA). Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1993.
13. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990;87:6574-8.
14. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-13.
15. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
16. Lasky L, Nakamura G, Smith DH, et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987;50:975-85.
17. Nakamura GR, Byrn R, Wilkes DM, et al. Strain specificity and binding affinity requirements of neutralization monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus typel. J Virol 1993;67:6179-91.